Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2 ) in combination with lenalidomide and dexamethasone.
Korde N, Mastey D, Tavitian E, Mailankody S, Lesokhin A, Hassoun H, Smith EL, Lendvai N, Hultcrantz M, Shah U, Tan C, Lu S, Diamond B, Salcedo M, Werner K, Chung DJ, Scordo M, Shah GL, Lahoud O, Landau H, Arcila M, Ho C, Roshal M, Dogan A, Derkach A, Devlin SM, Giralt SA, Landgren O.
Korde N, et al. Among authors: shah gl, shah u.
Am J Hematol. 2021 Jun 1;96(6):E193-E196. doi: 10.1002/ajh.26150. Epub 2021 Mar 19.
Am J Hematol. 2021.
PMID: 33661527
Free PMC article.
Clinical Trial.
No abstract available.